Systemic lupus erythematosus (SLE) is a multigenic systemic autoimmune disease with an immune complex--associated pathology that is prevalent among females of childbearing age. A hallmark of SLE is the appearance of serum antinuclear antibodies (ANAs) that appear to be products of T cell--dependent immunity, manifested by high-avidity binding, somatic mutations, and derivation from B cells that have undergone substantial clonal expansion ([@bib56], [@bib58]; [@bib63]). SLE-associated antibodies are frequently, but not exclusively, directed against histones, double-stranded DNA (dsDNA), histone--DNA complexes, and various ribonuclear proteins.

Considerable progress in dissecting SLE etiology and pathogenesis has come largely from mouse models with a genetic predisposition for spontaneous SLE-like disease ([@bib65]). These models have been especially useful in identifying genetic contributions to specific disease manifestations and the role played by toll-like receptors (TLRs) in targeting the autoimmune response to specific TLR agonists ([@bib12]; [@bib55]). Spontaneous SLE-like disease in F1 hybrid mice between the NZB strain and several others bears striking resemblance to human SLE with respect to manifestations, genetics, and female gender bias. Genetic backcross studies involving NZB mice have identified a gene-rich interval at the distal end of the NZB chromosome 1 that is strongly associated with spontaneous autoantibody development ([@bib69]). This region is syntenic with a region of distal chromosome 1 associated with human SLE ([@bib68]).

A complementary body of work investigating immunological self-tolerance has identified several mechanisms of tolerance that are potentially breached in systemic autoimmunity. With respect to the B cell, these mechanisms involve anergy, receptor editing, clonal deletion, and a less well defined preplasma cell checkpoint ([@bib17]; [@bib8]; [@bib40]). Studies of self-tolerance in B cells have relied heavily on mice carrying Ig transgenes that encode autoantibodies to artificial or natural self-antigens. In these models, self-tolerance is remarkably efficient, and autoantibody-encoding transgenes have, at most, a modest effect on development of ANAs ([@bib2]; [@bib37]; [@bib74]; [@bib61]; [@bib4]). When such transgenes are bred into autoimmune-prone strains, the autoreactive B cells that emerge are frequently oligoclonal and express edited receptors generated by endogenous Ig V gene rearrangements. Because it changes the unique identity of a B cell, receptor editing often obscures interpretations regarding the stages in B cell development when breaches in self-tolerance occur. Without this information, knowledge obtained from genetic mapping analyses, gene knockout studies, and other approaches cannot be fully interpreted in the context of disease etiology.

Many self-tolerance studies have focused on B cell developmental stages that precede immune activation, with the implicit assumption that autoreactive antecedents to disease-associated autoimmune B cells are generated in the bone marrow immediately after Ig gene recombination. Autoreactive cells generated in this manner would have to escape every self-tolerance checkpoint to participate in systemic autoimmunity ([@bib17]). Alternatively, autoimmune B cells in SLE may be created by somatic hypermutation (SHM) in mature activated B cells responding to antigens in the periphery. Autoreactive B cells generated via this mutation-founder scenario would have to traverse fewer tolerance checkpoints before participating in the autoimmune process. To distinguish between these alternatives, somatic mutations within V region genes of autoimmune B cells must be identified and reverted to germline sequence so that their contribution to the specificity and affinity of the autoreactive B cell receptor (BCR) can be evaluated. Efforts to interpret results of such analyses have been confounded by cell sampling issues, uncertainty over whether a cell expresses one or multiple receptors, and difficulties in identifying somatic mutations. Defining mutations is problematic because of V gene polymorphisms and the presence of untemplated nucleotides in the heavy chain third complementarity-determining region (CDR3 \[HCDR3\]) that are added by terminal deoxynucleotidyl transferase (Tdt) during Ig gene recombination ([@bib32]; [@bib16]). Yet defining mutations in HCDR3 is especially important because of its pivotal role in antigen binding, particularly with regard to nuclear antigens ([@bib31]; [@bib73]; [@bib34]; [@bib21]). The HCDR3 caveat was common to all preceding studies and likely contributed to mixed interpretations regarding the role of SHM in the origin of ANA ([@bib45], [@bib46]; [@bib59]; [@bib73]; [@bib70]; [@bib38]).

In this study, we used a model of spontaneous autoimmunity in which all somatic mutations in V region genes of ANA-producing hybridomas could be unequivocally identified for reversion analyses. We found frequent unambiguous cases in which high-avidity autoimmune B cells were created from nonautoreactive precursors by SHM.

RESULTS
=======

An SLE model for optimal identification of somatic mutations
------------------------------------------------------------

Our objective was to determine whether B cells producing ANAs in SLE-like disease were derived from precursors that emerge in the bone marrow with an autoreactive BCR or from somatic mutants generated in the periphery. To this end, we generated a mouse in which all somatic mutations in monoclonal autoreactive antibodies could be unequivocally identified, even in HCDR3. This was accomplished by breeding two copies of a targeted null *Tdt* allele into an autoimmune-prone C57BL/6.NZB*-Nba2* mouse (B6.*Nba2*; [@bib16]). The *Nba2* interval spans ∼20 centimorgans of DNA from distal chromosome 1 of the NZB strain and confers upon aged mice a spontaneous autoimmunity with many of the classical hallmarks of SLE, including ANAs and a female gender bias ([@bib51]). Notably, the chromosome 1--distal *Nba2* interval is syntenic with a distal region of human chromosome 1 that is genetically associated with SLE ([@bib68]). As such, the *Nba2* strain is considered an excellent model of spontaneous ANA development in human SLE. In *Tdt*-null mice, diversity at the borders of assembling gene segments is still created as a result of gain or loss of nucleotides, but the gains, referred to as P elements, occur through a templated process after the opening of sealed hairpins at the ends of coding segments ([@bib32]). Prior studies established the feasibility of this approach by demonstrating ANA in *Tdt*-deficient autoimmune mice ([@bib7]; [@bib39]).

In the absence of Tdt, somatic mutations in HCDR3 of ANAs can be clearly defined. It is equally important that somatic mutations in V~H~, D~H~, J~H~, and J~L~ gene segments used by such antibodies can also be unambiguously identified because the genomic sequence of the C57BL/6 strain is known. Heterozygous deficiencies in the Ig heavy chain (Igh) and kappa light chain (Igk) loci were also introduced because B cells may express both kappa and heavy chain alleles as a result of receptor editing or failed allelic exclusion ([@bib5]; [@bib19]). The heterozygous deficiencies limited expression to one heavy chain allele and made it possible to determine whether an autoreactive B cell hybridoma was expressing two light chains (κ + λ; [@bib15]; [@bib35]; [@bib50]). The heterozygous *Igh* deficiency also assisted in distinguishing P-element additions from somatic mutations at the boundaries of the gene segments encoding HCDR3. As such, the genetic makeup of the B6.*Nba2 Tdt^−/−^* *Igh^+/−^* *Igk^+/−^* mouse allowed us to determine and reconstruct the original unmutated sequences of spontaneously arising ANAs before the advent of SHM.

Anti-chromatin antibodies in B6.*Nba2 Tdt^−/−^* *Igh^+/−^* *Igk^+/−^* mice
--------------------------------------------------------------------------

As is typical of the B6.*Nba2* strain, a majority of aged female B6.*Nba2 Tdt^−/−^ Igh^+/−^ Igk^+/−^* mice developed high titers of serum anti-chromatin antibodies ([Fig. 1 A](#fig1){ref-type="fig"}). In most animals examined (6/8), these antibodies had already appeared by 5 mo of age. From one such spontaneously diseased mouse, we generated B cell hybridomas. In addition to anti-chromatin antibodies, this animal had substantial deposits of IgG in glomeruli of kidneys, as assessed by immunofluorescence (unpublished data). A screen of hybridoma supernatants for IgG antibodies directed against chromatin in a solid-phase europium-based immunoassay indicated that ∼5.7% (103/1,800) of them were positive. Representative results of a chromatin-binding assay using highly purified antibodies from several recloned hybridomas are shown in [Fig. 1 B](#fig1){ref-type="fig"}. The binding avidity of many of these antibodies was similar to, and sometimes exceeded, that of the prototypical ANA 3H9/Vκ4, which has served as a basis for numerous Ig transgene studies of tolerance and autoimmunity ([@bib56]).

![**Chromatin-binding IgG antibodies in B6.*Nba2 Tdt^−/−^ Igh^+/−^ Igk^+/−^* mice.** (A) Serum titers of IgG anti-chromatin antibodies from B6.*Nba2 Tdt^−/−^ Igh^+/−^ Igk^+/−^* mice (8--10 mo old). Red line, representative serum from a nonautoimmune C57BL/6 mouse. Standard errors are shown. (B) Chromatin binding assay with purified monoclonal antibodies generated from a spontaneously autoimmune B6.*Nba2 Tdt^−/−^ Igh^+/−^ Igk^+/−^* mouse (female, 12 mo old). A prototypical ANA, 3H9/Vκ4, is shown in red. Bound antibodies were detected in a solid-phase europium (Eu^3+^)-based fluoroimmunometric assay (as counts per second). The figure shows one of two experiments with similar results.](JEM_20092712R_RGB_Fig1){#fig1}

Heavy and light chain V region genes were sequenced for 30 of the hybridomas using a reverse transcriptase PCR procedure. The sequences were queried against entries in several databases, most notably the National Center for Biotechnology Information C57BL/6 genome Build 36.0, to identify corresponding germline V gene segments used by each hybridoma. Unambiguous matches for V~H~, D~H~, J~H~, and J~k~ gene segments were found in every case and permitted somatic mutations to be identified clearly ([Supplemental data](http://www.jem.org/cgi/content/full/jem.20092712/DC1)). In a few cases, the heterozygous deficiency at the Igh locus also aided in the identification of mutations located at the gene segment boundaries. For example, we were able to infer that a thymidine nucleotide in the V~H~/D boundary in hybridomas J6.1 and J5.5 (lineage 4; [Fig. 2](#fig2){ref-type="fig"}) was added in a templated manner (P element) during V gene segment assembly. Had it been inserted instead via SHM, the preceding sequence would have been shifted out of the proper translational reading frame by 1 base and unable to encode a BCR, which is required for B cell survival.

![**HCDR3 sequences for clones subjected to mutation-reversion analysis.** Germline-encoded D~H~ sequences are shown above and germline-encoded V~H~ and J~H~ sequences are shown below hybridoma (shaded) sequences. Somatic mutations are underlined. The blue lowercase t in J6.1 is a templated nucleotide (P element) added during V~H~(D)J~H~ recombination. In lineage \#4, somatic mutations that eliminated Arg codons are explicitly indicated for both members.](JEM_20092712_RGB_Fig2){#fig2}

V region gene sequences revealed that the 30 hybridomas represented 12 antecedent B cell clones. Seven clones were represented by one hybridoma each. Four clones were represented by two hybridomas each, and one large clone was represented by 15 hybridomas ([Fig. 3](#fig3){ref-type="fig"}). This indicated that half of the chromatin-reactive hybridomas that were sampled represented one large clone. Large lineages of autoimmune B cells in spontaneous SLE are common, as they have been seen in several other studies ([@bib53]; [@bib6]; [@bib76]).

![**Dendrograms of multimember lineages.** Numbers of somatic mutations are indicated along each branch, where r denotes an amino acid replacement and red indicates a mutation shared by all members of the lineage. The length of a branch is proportional to the number of somatic mutations. Clones from the first animal subjected to reversion are colored green, and those from a second autoimmune mouse are in yellow. Four of seven clones from the first animal that were represented by single hybridomas and subjected to reversion are shown.](JEM_20092712R_RGB_Fig3){#fig3}

Structural evidence that autoreactivity was generated via SHM
-------------------------------------------------------------

Several key observations emerged from the sequence analyses to support the idea that the chromatin reactivity of these antibodies was generated by SHM. First, every antibody was encoded by somatically mutated V region genes, carrying from 2 to 24 aa replacements ([Table I](#tbl1){ref-type="table"}). Second, each multimember lineage was defined by shared somatic mutations producing amino acid replacements among all clone members ([Fig. 3](#fig3){ref-type="fig"}). This is a prediction of the mutation-founder scenario. In the large lineage \#1, for example, all members shared 17 somatic mutations, 15 of which produced amino acid replacements. A strong selection event apparently drove the proliferation of a single mutated B cell relative to its siblings at or near the time it had acquired the 17th somatic mutation. At this point, we infer that the cell was strongly autoreactive because an engineered antibody containing only these shared mutations bound strongly to chromatin (unpublished data). Third, 11 of 12 clones carried somatic mutations producing arginine (Arg) residues, and in four of the five multimember lineages, there was at least one mutation producing a shared Arg replacement among clone members ([Table I](#tbl1){ref-type="table"} and Supplemental data). Arg residues are often critical for antinuclear specificities ([@bib44]; [@bib28]; [@bib31]; [@bib26]; [@bib34]; [@bib47]; [@bib64]; [@bib21]; [@bib22]). Studies with DNA-binding proteins have shown that their flexible side chains can interact via hydrogen bonds with bases in the major and minor grooves of DNA or form salt bridges and hydrogen bonds with the phosphodiester backbone ([@bib62]; [@bib36]). One of the two shared arginine mutations in lineage \#1 occurred in HCDR3 at the boundary of the DFL16.1 gene segment and the J~H1~ gene segment ([Fig. 2](#fig2){ref-type="fig"}). Had this clone been derived from a mouse with a functional gene for Tdt, we would not have been able to draw this conclusion with confidence. However, although HCDR3 arginines are often associated with affinity for nucleic acids, this is not always the case ([@bib47]). In HCDR3 of lineage \#4, a pair of Arg codons sustained nonsynonymous somatic mutations. In hybridoma J5.5, a *V*~H~ Arg codon near the boundary with the D gene segment was mutated to a Thr codon ([Fig. 2](#fig2){ref-type="fig"}). In the other hybridoma of lineage \#4 (J6.1), a mutation at the beginning of the D gene segment produced an Arg to Ser codon conversion ([Fig. 2](#fig2){ref-type="fig"}).

###### 

Summary of hybridoma V region genes

  Hybridoma                                Vκ germline genes and shared mutations; shared replacements[a](#tblfn1){ref-type="table-fn"}   Mutations: total; replacements   V~H~ germline genes, isotype, and shared mutations; shared replacements   Mutations: total; replacements   Unanimously shared Arg mutations
  ---------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------- ------------------------------------------------------------------------- -------------------------------- ---------------------------------------------
  **Lineage \#1 (mouse 1)**                                                                                                                                                                                                                                                           
  J1.1                                     Vκ CR-1/Jκ2 unanimously shared mutation10; 8r                                                  15; 9r                           VH7183.9.15/ DFL16.1/ JH1 γ2b unanimously shared mutations 7r             11; 10r                          0 Vκ; 2 VH
  J1.4                                                                                                                                    13; 9r                                                                                                     13; 11r                          0 Vκ; 2 VH
  J2.6                                                                                                                                    14; 9r                                                                                                     9; 8r                            0 Vκ; 2 VH
  J2.7                                                                                                                                    14; 10r                                                                                                    10; 8r                           0 Vκ; 2 VH
  J3.1                                                                                                                                    12; 8r                                                                                                     8; 7r                            0 Vκ; 2 VH
  J3.4                                                                                                                                    10; 8r                                                                                                     13; 9r                           0 Vκ; 2 VH
  J3.8                                                                                                                                    11; 9r                                                                                                     11; 8r                           0 Vκ; 2 VH
  J4.2                                                                                                                                    10; 8r                                                                                                     11; 9r                           0 Vκ; 2 VH
  J5.8                                                                                                                                    14; 9r                                                                                                     9; 8r                            0 Vκ; 2 VH
  K5.14                                                                                                                                   14; 9r                                                                                                     9; 8r                            0 Vκ; 2 VH
  J7.18                                                                                                                                   14; 8r                                                                                                     13; 9r                           0 Vκ; 2 VH
  J9.7                                                                                                                                    13; 8r                                                                                                     12; 10r                          0 Vκ; 2 VH
  J10.7                                                                                                                                   10; 8r                                                                                                     13; 9r                           0 Vκ; 2 VH
  J10.13                                                                                                                                  11; 8r                                                                                                     11; 7r                           0 Vκ; 2 VH
  K6.23                                                                                                                                   13; 9r                                                                                                     7; 7r                            0 Vκ; 2 VH
  **Lineage \#2 (mouse 1)**                                                                                                                                                                                                                                                           
  J2.8[b](#tblfn2){ref-type="table-fn"}    Vκ ai4/ Jκ1 unanimously shared mutations 1r                                                    2; 2r                            VH3609.12.174/ DSP2.2/JH1 γ2c/γ2b unanimously shared mutations 2; 1r      2; 1r                            0 Vκ; 0 VH
  J7.13[b](#tblfn2){ref-type="table-fn"}                                                                                                  1; 1r                                                                                                      5; 2r                            0 Vκ; 0 VH
  **Lineage \#3 (mouse 1)**                                                                                                                                                                                                                                                           
  J3.7                                     Vκ CR-1/Jκ1 unanimously shared mutations 3; 2r                                                 19; 12r                          VHJ558.59.155/DSP2.2/JH3 γ1 unanimously shared mutations 3; 2r            21; 12r                          0 Vκ; 1 VH[c](#tblfn3){ref-type="table-fn"}
  K6.18                                                                                                                                   11; 7r                                                                                                     11; 9r                           0 Vκ; 1 VH
  **Lineage \#4 (mouse 1)**                                                                                                                                                                                                                                                           
  J5.5                                     Vκ 23-43 /Jκ5 unanimously shared mutations 1r                                                  5; 4r                            VHQ52.2.4/DST4/ JH2 γ2c Unanimously shared mutations 6; 3r                10; 5r                           1 Vκ; 0 VH
  J6.1                                                                                                                                    4; 3r                                                                                                      9; 6r                            1 Vκ; 0 VH
  **Lineage \#5 (mouse 1)**                                                                                                                                                                                                                                                           
  J3.9                                     Vκ ai4/ Jκ2 unanimously shared mutations 6r                                                    9; 8r                            VHJ558.26.116/DQ52/JH3 γ1 unanimously shared mutations 5r                 8; 6r                            3 Vκ; 1 VH
  J3.10                                                                                                                                   7; 7r                                                                                                      15; 9r                           3 Vκ; 1 VH
  **Single clones (mouse 1)**                                                                                                                                                                                                                                                         
  J3.11                                    Vκ ai4/ Jκ5                                                                                    11; 7r                           VHJ558.26.116/DSP2.5/ JH2 γ2c                                             25; 15r                          1 Vκ; 0 VH
  J3.12                                    Vκ aa4/ Jκ1                                                                                    2; 0r                            VH7183.20.37/DSP2.x/JH4 γ2c                                               13; 11r                          0 Vκ; 1 VH
  J6.2                                     Vκ 23-39/Jκ2                                                                                   17; 9r                           VHJ558.79.184/DST4/JH4 γ2c                                                16; 9r                           1 Vκ; 1 VH[d](#tblfn4){ref-type="table-fn"}
  J9.11                                    Vκ 23-45/Jκ4                                                                                   1; 1r                            VHJ558.75.177/DSP2x/JH1 γ2c                                               1; 1r                            1 Vκ; 0 VH
  J10.12                                   Vκ19-25/Jκ1                                                                                    7; 5r                            VH3609.12.174/ DSP2.x/JH1 γ2c                                             4; 4r                            0 Vκ; 1 VH
  J10.24                                   Vκ ai4/Jκ2                                                                                     8; 4r                            VHJ558.26.116/DSP2.2/JH2 γ1                                               3; 3r                            1 Vκ; 0 VH
  K6.16                                    Vκ 23-43/Jκ2                                                                                   10; 6r                           VHJ588.2.88/ DFL16.1/JH2 γ1                                               18; 11r                          1 Vκ; 1 VH
  **Lineage \#6 (mouse 2)**                                                                                                                                                                                                                                                           
  N3.18                                    Ai4/Jk2                                                                                        7; 4r                            VHJ558.26.116/DSP2.5/JH4 γ2c                                              15;13r                           1 Vκ; 0 VH
  N12.6                                    Unanimously shared mutations 3; 1r                                                             13; 6r                           Unanimously shared mutations 14; 12r                                      15;13r                           1 Vκ; 0 VH
  **Single clones (mouse 2)**                                                                                                                                                                                                                                                         
  Q10.4                                    23-43/Jk5                                                                                      4; 3r                            VHJ558.26.116/DFL16.1/JH1 γ2c                                             2; 1r                            1 Vκ; 0 VH

Empty cells in the second and fourth columns indicate the same information as the cell above.

Amino acid replacements due to somatic mutation.

J2.8 is γ2c; J7.13 is γ2b.

Members of this clone share an Arg replacement in VH CDR1 but as a result of different base substitutions (mutations).

Arg codon may be the result of either a somatic mutation in CDR3 or a P-element addition.

Finally, few of the clones showed signs of light chain receptor editing ([@bib14]; [@bib66]). None of the antibodies expressed a lambda light chain, and only 3 of the 12 clones used distal J~k5~ or J~k4~ gene segments ([Table I](#tbl1){ref-type="table"}). This is approximately the frequency expected for clones attempting to negotiate a productive rearrangement. Collectively, these structural observations were consistent with the idea that many of the chromatin-reactive B cells were derived from nonautoreactive B cells in secondary lymphoid tissues via the process of SHM.

A large autoreactive lineage derived from a nonautoreactive B cell
------------------------------------------------------------------

To test the mutation-founder idea conclusively, we reverted the 15 nonsynonymous mutations shared by all members of the large lineage \#1 to regenerate codons expressed by the original B cell as it emerged in the bone marrow before SHM. These included the HCDR3 somatic mutations, as illustrated in [Fig. 2](#fig2){ref-type="fig"} (top sequence). The primers used to construct the template for reversion mutagenesis were located distally with respect to the variable gene coding sequences to accurately recreate all features of the unmutated (and mutated) variable genes, including the leader sequences. This was done because mutations in leader sequences can affect antibody binding ([@bib43]). The reverted constructs were transfected in the context of an IgG2b genomic expression vector into SP2/0 cells to produce antibody, which was affinity purified and treated with DNase and 1 M NaCl to remove potential contaminating nuclear antigens as previously described ([@bib21]). This was done because unpurified ANAs from culture supernatants can display altered binding specificity and avidity profiles as a result of contaminating nuclear antigens that may form a bridge between the antibody and an intended target antigen in immunoassays.

Binding immunoassays revealed that the revertant Ab of lineage \#1 lost all measurable affinity for chromatin, as well as for various nuclear antigen subspecificities ([Fig. 4](#fig4){ref-type="fig"}). The revertant also failed to demonstrate detectable antinuclear activity against fixed HEp-2 cells by immunofluorescence, even when used at a substantially higher concentration than that of the original mutant antibody ([Fig. 5 A](#fig5){ref-type="fig"}). Finally, the revertant failed to bind detectably any tissue antigen in frozen sections of whole neonatal mice, as assessed by immunofluorescence ([Fig. 5 B](#fig5){ref-type="fig"}). To validate our IgG2b transfection vector and procedure, we also reconstructed the original mutant antibody and expressed it in SP2/0 cells. The mutant Ab generated in this way retained its original activity, as expected (unpublished data). On the basis of these results, we conclude that the largest chromatin-reactive clone was derived from a normal B cell whose antinuclear specificity was created by SHM.

![**Chromatin binding assays for monoclonal antibodies and engineered revertants lacking somatic mutations.** Standard errors are shown. R and red font color denote germline revertants. Two of the original monoclonal antibodies (J3.4 and J9.11) demonstrated binding activity against several chromatin components as shown in B--D. All antibodies were purified by a stringent affinity method designed to remove potentially contaminating nuclear antigens ([@bib21]). A prototypical ANA, 3H9/Vκ4, is shown in blue in A. Bound antibodies were detected in a solid-phase europium (Eu^3+^)-based fluoroimmunometric assay (as counts per second). One of three experiments with similar results is shown.](JEM_20092712R_RGB_Fig4){#fig4}

![**Immunofluorescence staining of HEp-2 cells and whole frozen sections of neonatal mouse with monoclonal antibodies and engineered revertants without somatic mutations.** (A) Stains of fixed HEp-2 cells. R and red font color denote revertant. Note higher concentrations used for revertant antibodies. 3H9/Vκ4 and 36--71 served as positive and negative controls, respectively. The experiment was performed three times. Bar, 100 µm. (B) Stains of whole frozen sections of neonatal mice. Mutant antibody J6.1 served as positive control. Experimental section was stained with a mixture of revertant antibodies (RJ3.4, RJ9.11, and RJ6.1), each at a concentration equivalent to that of the positive control J6.1 mAb. Bound positive antibodies were detected with an FITC-coupled sheep anti--mouse IgG (γ-chain specific). Sections were counterstained with DAPI (blue) to highlight organs (In, intestine; Li, liver; K, kidney; Lu, lung; H, heart; Br, brain; E, eye). One of two experiments with similar results is shown. Bar, 3 mm.](JEM_20092712R_RGB_Fig5){#fig5}

Other autoreactive clones created by SHM
----------------------------------------

To determine whether mutation-generated autoreactivity in the large clone was the exception or the rule, we interrogated additional independent clones by reversion analysis. As a rigorous test, we initially chose three clones with characteristics suggesting that they might have emerged with antinuclear BCR directly from the bone marrow. Lineage \#2 was chosen because no Arg replacement mutations were shared by its two members. Lineage \#4 was selected because its two members used a J~k5~ gene segment, suggesting that the clone may have exhausted options for receptor editing in attempts to replace an autoreactive BCR. A third clone (J9.11) was chosen because its antibody V genes contained the fewest number of nonsynonymous somatic mutations (only 2) among the 30 clones that were examined. In addition, it also used a distal J~k4~ gene segment. All antibodies were purified as described for lineage \#1 and tested in various binding assays. Despite their structural features, each of these clones sustained dramatic losses in autoreactivity activity upon mutation reversion, completely in two cases and ∼50-fold in the third ([Figs. 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). In addition, neither the revertants nor the original mutant mAb bound to cardiolipin detectably ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20092712/DC1)). As with lineage \#1, the transfection and expression methods were validated by recreating and expressing the three mutants in the context of the IgG2b expression vector. In each case, autoreactivity was preserved.

As a final test, we reverted the somatic mutations in six additional ANA-producing clones. Two of these were from a second 8-mo-old autoimmune female mouse with serum anti-chromatin IgG, although of a lower titer than previous mouse. Only ∼0.5% of the hybridomas (4/832) from this animal was initially scored positive for IgG anti-chromatin. One of these clones was represented by two hybridomas ([Fig. 3](#fig3){ref-type="fig"}). The other 4 clones were from the original set of 12 derived from the first animal. In every case, the germline revertants lost all detectable autoreactivity as assessed in solid-phase binding assays against chromatin, in immunofluorescence assays against fixed HEp-2 cells, and in immunofluorescence assays against whole frozen sections of neonatal mice ([Figs. S1--4](http://www.jem.org/cgi/content/full/jem.20092712/DC1)). It is clear from these analyses that SHM frequently created antinuclear clones from nonautoreactive precursors; in 9 of 10 clones, SHM was responsible for all detectable autoreactivity and in the 10th clone for almost all of it.

The precursor to an ANA-producing clone generated by V~H~ gene replacement
--------------------------------------------------------------------------

The absence of Tdt in these autoimmune mice enabled us to define the origins of nucleotides at junctional boundaries of assembled V, D, and J gene segments encoding the ANA in our panel. Clone Q10.4 was unusual because it had 8 bases at the V~H~/D boundary that were derived neither from the corresponding V~H~J558.26.116 and DFL16.1 gene segments nor from a P-element addition ([Fig. 6 A](#fig6){ref-type="fig"}). To determine if this short sequence was a residual footprint left by a V~H~ gene replacement event ([@bib30]; [@bib49]; [@bib77]), we searched 1.2 megabases of B6 genomic DNA located downstream of the *V~H~J558.26.116* gene for this sequence (GAGACAGA). This region of DNA included all V~H~ genes located between *V~H~J885.26.116* and the D gene segment cluster, any one of which was a potential candidate for replacement by a secondary rearrangement involving *V~H~J558.26.116*. The GAGACAGA sequence was found 60 times. For each of the 60 hits, we extracted the preceding 300 bases and performed an Ig BLAST search to determine if they encoded a V~H~ gene in any reading frame. This analysis produced one V~H~ gene (*V~H~12.1.78*) that contained the GAGACAGA sequence precisely at its 3′ end. This V~H~ gene also contained a cryptic heptamer recombination signal sequence located 3 bases immediately 5′ of GAGACAGA. When the translational reading frame of *V~H~12.1.78* was extended through the recombined V~H~/D junction, it terminated in two consecutive stop codons within the DFL16.1 gene segment ([Fig. 6 B](#fig6){ref-type="fig"}). These observations reveal that the Q10.4 ANA clone had traversed a circuitous pathway to autoimmunity. It had originally carried a nonproductive *V~H~12.1.78/DFL16.1/J~H1~* gene in which *V~H~12.1.78* was subsequently replaced by *V~H~J558.26.116* to generate a productive heavy chain gene. After V~k~ gene rearrangement, it is possible that the original B cell was autoreactive and underwent receptor editing, as suggested by the use of J~k5~. Alternatively, several V~k~ recombination events terminating in a V~k~-J~k5~ exon may have been required to produce the first functional kappa gene. Either way, subsequent SHM then generated the autoreactive nuclear specificity in this cell. To our knowledge, this is the first demonstration of an endogenous V~H~ gene replacement that corrected a naturally occurring nonproductive V/D/J rearrangement.

![**Functional Igh gene for the Q10.4 hybridoma created by V~H~ replacement.** (A) The Q10.4 V~H~/D/J~H~ boundary sequence illustrating an 8-base sequence remaining from the original *V~H~12.1.78* rearrangement in red. (B) The original *V~H~12.1.78* rearrangement showing the nonproductive translational reading frame ending in consecutive stop codons (red). The cryptic heptamer recombination signal sequence within *V~H~12.1.78* is shown in blue. The 8-base sequence of *V~H~12.1.78* that is destined to remain after replacement by *V~H~J558.26.116* is also shown in red.](JEM_20092712_RGB_Fig6){#fig6}

A propensity for arginine mutations at specific serine codons
-------------------------------------------------------------

Many studies have indicated the important role of Arg residues in antinuclear activity ([@bib44]; [@bib28]; [@bib31]; [@bib26]; [@bib34]; [@bib47]; [@bib64]; [@bib21]; [@bib22]). In agreement with this, when the single Arg replacement mutation in the J9.11 clone (V~k~ CDR1) was reverted to a germline serine codon, there was nearly a complete loss of anti-chromatin activity in the resultant antibody ([Fig. S5](http://www.jem.org/cgi/content/full/jem.20092712/DC1)). Arg mutations can also impart positive charges to antibodies, and there are studies reporting that cationic ANAs are prone to deposit in the kidney and induce pathology ([@bib11]; [@bib9]). Although several of our antibody V regions with Arg mutations had relatively high calculated isoelectric points (pI = 9.1--9.4), we did not see evidence of pathology when they were injected (as hybridomas) into irradiated BALB/c mice (unpublished data).

A close inspection of all Arg mutations within our panel of hybridomas revealed that a majority of them occurred at AGC and AGT serine codons. 40% of independent Arg mutations in V~H~ and V~k~ genes expressed by our hybridoma panel were at AGC ([Table II](#tbl2){ref-type="table"}). This is likely a result of the fact that AGC is the most intrinsically favored triplet target of SHM and because AGC can mutate to an arginine codon by any 1 of 3 different single base changes ([@bib60]). In addition, the AGC codon is well represented in Ig V genes of our hybridoma panel; it is present in the V~k~ and V~H~ genes at approximately two and three times the frequency expected for random codon use, respectively. Although AGT is not a prefered target of SHM, it is also well represented in the V~H~ and V~k~ genes of our panel, at 2.2 and 6.6× the frequency expected for random codon use ([Table II](#tbl2){ref-type="table"}). Moreover, the combined frequencies of AGC and AGT in CDR1 and CDR2 are even higher, at 4.3 (V*~H~*) and 7.1 (V~k~)× that expected. This is reminiscent of an observation reported by [@bib44] that among the six serine codons, AGC and AGT were overrepresented in CDR of a sample of ANA V genes. Collectively, mutations at AGC and AGT accounted for 66% (20/30) of all Arg mutations in the V genes of our panel.

###### 

Frequent Arg mutations at AGC and AGT codons in V genes

  V genes   Arg mutations at AGC   Arg mutations at AGT   AGC codons in V genes[a](#tblfn5){ref-type="table-fn"}   AGT codons in V genes   AGC+AGT CDR1 and CDR2   AGC+AGT FR1 and FR2
  --------- ---------------------- ---------------------- -------------------------------------------------------- ----------------------- ----------------------- ---------------------
            *%*                    *%*                    *%*                                                      *%*                     *%*                     *%*
  V~H~      41.7                   16.7                   3.7                                                      2.0                     10.8                    1.8
  V~κ~      38.9                   33.3                   3.0                                                      6.1                     17.9                    1.9

This table refers to anti-chromatin antibodies in this study.

AGC and AGT codon usage among 52,926 mouse genomic codons is 1.6 and 0.92%, respectively (GenBank: <http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=10092>).

These observations prompted us to analyze codon use by all C57BL/6 Ig V~H~ and V~k~ genes listed in the Ig Blast public database (<http://www.ncbi.nlm.nih.gov/igblast/>). This analysis revealed that AGC was used ∼1.9× more frequently in V~H~ genes and 1.6× more frequently in V~k~ genes than expected on the basis of either random codon use or actual codon use by other mouse genes. AGT use by mouse V genes was even higher ([Table III](#tbl3){ref-type="table"}). Finally, similar results for both codons were seen when all human V~H~ and V~k~ and V~λ~ genes in the BLAST Ig database were analyzed. The results were nearly the same when only one allele (listed first in the database) for each of the human V genes was analyzed. Collectively, these observations support the idea that SHM frequently creates nuclear-reactive B cell clones from normal B cell clones and that this occurs by mutations that convert AGC and AGT serine codons to arginine codons.

###### 

Frequent use of AGC and AGT codons in antibody V genes

  V genes   AGC codon use   AGT codon use          
  --------- --------------- --------------- ------ -----
            \%              \%              \%     \%
  V~H~      3.1             3.4             1.67   2.2
  V~κ~      2.6             3.9             5.5    4.7
  V~λ~      2.4             3.4             2.4    2.4

This table shows V gene sequences taken directly from Ig BLAST (<http://www.ncbi.nlm.nih.gov/igblast/>). A majority of the Ig BLAST sequences were from the international ImMunoGeneTics information system (IMGT; <http://www.imgt.org>).

AGC and AGT codon usage among 52,926 mouse genomic codons is 1.6 and 0.92%, respectively (GenBank: <http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=10092>).

AGC and AGT codon usage among 40,662,582 human genomic codons is 1.95 and 1.21%, respectively (GenBank: <http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=9606>).

DISCUSSION
==========

The results of this study provide conclusive evidence that SHM generates spontaneous autoreactive B cells that participate in systemic autoimmunity. By generating ANA-producing hybridomas from mice with a homozygous genetic deficiency in *Tdt* and heterozygous deficiencies at the Igh and Igk loci, we were able to unequivocally identify all of the somatic mutations in V region genes of spontaneous ANA-producing B cells and to test them functionally in reversion analyses. The requirement of somatic mutations for antinuclear activity was absolute in 9 of 10 clones analyzed and included a large lineage comprising approximately half of the sampled B cells. A predominant fraction of mutations producing Arg codons occurred at AGC and AGT serine codons, which are abundant in V genes and able to mutate to an Arg codon by 3 alternative base changes. AGC is also the most intrinsically mutable codon substrate for SHM. Considering the importance of Arg residues in antinuclear activity, these findings collectively support the idea that SHM routinely generates ANA-specific B cells during T cell--dependent immunity.

We are confident that all functionally relevant binding was lost in nine of the clones examined because multivalent immunoassays are so sensitive that they can reveal binding interactions that are below the threshold required for immune recruitment. In the arsonate (Ars) model, for example, a canonical antibody can be readily detected in immunoassays with protein conjugates of sulfanilic acid (Sulf), even though immunization with Sulf-carrier protein does not recruit cells producing this antibody ([@bib13]). Clone J7.13 is the one exception that retained a small measure of antinuclear activity after reversion, raising the possibility that it escaped all tolerance checkpoints in B cell development. Alternatively, the avidity of the germline antecedent of J7.13 for self-antigen may be physiologically irrelevant and insufficient to induce a tolerant phenotype. It is noteworthy that clone J7.13 used a J~k1~ gene segment. This could reflect insufficient avidity for self-antigen to induce receptor editing or a defect in receptor editing in B6.*Nba2* mice. Distinguishing between these can only be determined by generating mice that carry an unmutated version of this BCR and comparatively analyzing the resultant B cells in B6 and B6.*Nba2* mice.

Our approach avoided caveats that previously obscured complete identification of somatic mutations in disease-associated autoreactive B cells. Chief among these was the undefined nature of unmutated CDR3 sequences in antecedents to autoimmune clones. This was resolved by an absence of Tdt in our mice. The high resolution imparted by a Tdt deficiency is underscored by the fact that it enabled us to define, for the first time, an endogenous V~H~ gene replacement that corrected a naturally generated nonproductive V/D/J gene. The subset of prior studies that interpreted somatic mutations as being critical to ANA, particularly those involving human ANA, did not have the benefit of genetic ablations to define the role of somatic mutations in CDR3 and of secondary rearrangements to autoreactivity. Nevertheless, these preceding studies framed an important issue and provided the first evidence that somatic mutations were required for the generation of disease-associated ANA ([@bib45], [@bib46]; [@bib59]; [@bib73]; [@bib70]; [@bib33]; [@bib38]). Whether the conclusion of our study applies to autoantibodies in other autoimmune diseases is unknown. It is noteworthy, however, that in young children that progress to type I diabetes, the first anti-insulin antibodies detected in serum are high-avidity IgGs ([@bib42]; [@bib75]). This may be an indication that their insulin specificities are generated by SHM.

In testing the relevance of somatic mutations to the antinuclear activity of a given antibody, we took the precaution of eliminating all of them. This was done because preservation or improvement of a germline-determined affinity might require several somatic mutations, whereas a subset of the same mutations might be destructive. One somatic mutation might be functionally destructive if acquired before, but beneficial if acquired after, another mutation. The hybridoma sampling approach was also an important component of our approach. Many studies have demonstrated a strong concordance between serum antibodies and mAb produced by hybridomas sampled in physiological and disease settings ([@bib48]; [@bib18]; [@bib72]; [@bib57]). However, the relationship between serum ANA and receptors expressed by B cells bearing markers of memory is not as well defined. Cells sorted for memory markers might include a tolerant category, as suggested by the high frequency of antinuclear BCR specificities observed in such cells isolated from nonautoimmune individuals ([@bib67]) and by the observation that in mouse models of immunity to foreign antigens, autoreactivity tends to be purged during memory B cell development ([@bib41]; [@bib20]).

The patterns and frequencies of somatic mutations in our clones indicated that autoimmune B cells were generated at both early and late stages after induction of SHM. For example, some of the mutant antinuclear B cells carried few mutations, whereas members of the large lineage shared 17 somatic mutations, indicating strong selection at or near the time that the last shared mutation was acquired. SHM normally diversifies antibody genes during physiological responses to foreign immunogen within the microenvironment of the germinal center (GC). Therefore, the most straightforward interpretation of our results is that the mutant antinuclear B cells were generated de novo at this time ([@bib1]; [@bib25]). Although we favor this idea, it is conceivable that SHM and selection are not properly regulated and occur elsewhere in B6.*Nba2* mice. SHM outside of the GC has been reported for rheumatoid-factor B cells in one model of autoimmunity ([@bib71]). Either way, our results support the counterintuitive conclusion that a developing B cell emerging from the bone marrow with a normal nonautoreactive BCR may be more dangerous than one arising with an autoreactive BCR.

In autoimmune-prone mice that express transgenic antinuclear BCR, the autoimmune clones that ultimately arise in disease often express altered BCRs that are products of receptor editing. One possible explanation is that upon receptor editing, the precursors either replaced one autoreactive BCR with another or were unable to dilute the autoreactive BCR by expressing a second benign heavy or light chain gene. Our findings suggest an alternative possibility. Editing may have been functionally successful, thus permitting the B cells to survive early self-tolerance checkpoints, become engaged in an immune response, and undergo SHM to become autoreactive. A mature B cell that gains autoreactivity during immunity has to escape fewer tolerance checkpoints than one that emerges in the bone marrow with an autoreactive BCR.

Several observations support the idea that SHM frequently creates autoreactive B cells during the GC reaction. The varying numbers of shared somatic mutations in our lineages indicate that mutations creating antinuclear BCR can apparently be acquired at early or late time points after the commencement of SHM. In addition, there appears to be a bias favoring somatic mutations that generate Arg codons because of an abundance of specific serine codons in antibody V genes that have an intrinsic bias to mutate to Arg codons or are preferred targets of SHM. Nevertheless, previous studies have demonstrated one or more tolerance checkpoints at, or after, the GC phase of B cell differentiation ([@bib23]; [@bib8]). This raises an intriguing question: if ANA-specific B cells are frequently generated in the GC and must subsequently be censored, what is the major benefit of self-tolerance checkpoints during development of the preimmune B cell repertoire?

One possibility to consider is that early censorship offers the added benefit of preventing autoreactive B cells from competing with normal B cells for physical and functional niches in the immune system. As such, central tolerance in the preimmune repertoire may ensure that it is populated with B cells that are most likely to generate successful progeny if recruited into an immune response. From this perspective, receptor editing and deletion of autoreactive B cells in the preimmune repertoire may be viewed as quality control measures that ultimately enhance immune responses. The existence of receptor editing as a potential salvage operation supports the idea that generating a functional B cell repertoire is a difficult or energetically expensive prospect, otherwise deletion should suffice. This idea is also supported by microsequence substrate preferences of the SHM mechanism, which has an intrinsic target bias to limit structural damage to the V region ([@bib10]; [@bib29]; [@bib54]). This quality control idea leads to the prediction that defects in receptor editing and deletion of autoreactive B cells in the preimmune repertoire would result in compromised humoral immunity.

MATERIALS AND METHODS
=====================

### Mice.

B6.*Nba2* congenic mice were described previously and were provided by S. Rozzo and B. Kotzin (University of Colorado Health Sciences Center; Denver, CO; [@bib51]). Tdt-deficient mice were provided by D. Mathis (Harvard University, Cambridge, MA; [@bib16]). Kappa gene-deficient mice were provided by D. Huszar (AstraZeneca R&D Boston, Waltham, MA; [@bib5]) and heavy chain gene--deficient mice ([@bib19]) were purchased from The Jackson Laboratory. All loci were previously bred onto a B6 genetic background and intercrossed to generate B6.*Nba2 Tdt* ^−/−^ *IgH*^+/−^ *Igk^+/−^* mice in the Biological Resource Center at National Jewish Health. All animals were handled according to a protocol approved by the Institutional Animal Care and Use Committee of National Jewish Health. Genotyping was performed by PCR with primers shown in [Table S1](http://www.jem.org/cgi/content/full/jem.20092712/DC1).

### Hybridoma production.

Hybridomas were generated from a 12-mo-old B6.*Nba2 Tdt* ^−/−^ *IgH*^+/−^ *Igk^+/−^* spontaneously autoimmune mouse using the SP2/0/ mIL-6 fusion partner ([@bib24]). Hybridoma culture supernatants were tested for the production of IgG antibodies in a Eu^+^-linked fluoroimmunoassay using a goat anti--mouse IgG H-chain--specific antibody (SouthernBiotech) as described in Antibody binding assays. Hybridomas that scored positive were cloned by limiting dilution. Heavy chain isotypes of monoclonal antibodies were determined by ELISA using an isotyping kit (SouthernBiotech).

### Sequencing hybridoma V region genes.

Variable genes of the hybridomas were cloned with RT-PCR and 5′ rapid amplification of cDNA ends (RACE) using sets of constant region primers and anchor primers. Total RNA was isolated from the hybridomas with RNeasy (QIAGEN), and first-strand cDNA was synthesized with Superscript III RT (Invitrogen) using an oligo (dT) primer. First-strand cDNA was purified using QIAquick (QIAGEN), and a poly (dG) tail was added to 3′ ends with Tdt (Invitrogen) at 37°C for 20 min in the presence of 0.4 mM dGTP. First-round 5′ RACE PCR was performed on 5 µl of tailed cDNA using high-fidelity Phusion DNA polymerase (Finnzymes) with anchor primer 1 and a heavy chain or light chain constant region outer primer (Table S1) under the following conditions: an initial incubation at 98°C for 1 min; then 18 cycles at 98°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and a final incubation at 72°C for 10 min. Second-round PCR was performed on 1 µl of first-round PCR product with anchor primer 2 and a nested constant region heavy chain or light chain primer under the following conditions: an initial incubation at 98°C for 1 min; then 20 cycles of 98°C for 30 s, 60°C for 30 s, and 72°C for 1 min; and a final incubation at 72°C extension for 10 min. Heavy chain PCR products were extracted from 2% agarose gels and inserted into the pCR4-TOPO vector (Invitrogen). Light chain PCR products were purified with QIAquick and digested with restriction enzymes PflFI or PflmI (New England Biolabs, Inc.) to disrupt the rearranged *V~k~21-12* gene transcribed by the SP2/0 fusion partner (only three other kappa genes have both restriction sites). After 2% agarose gel electrophoresis of the PCR products, the uncut bands were extracted and inserted into pCR-4-TOPO for sequencing. DNA sequencing was performed with BigDye terminator mixtures in conjunction with a 3100 capillary sequencer (Applied Biosystems) at the University of Colorado Cancer Center DNA Sequencing and Analysis Core Facility (Aurora, CO).

### Sequence analysis.

To identify germline precursors of expressed hybridoma V~H~ and V~k~ gene segments, the latter were aligned against the entire B6 genome reference sequence (National Center for Biotechnology Information build 36) using mouse Blast (<http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090>) and Ig Blast ([www.ncbi.nlm.nih.gov/projects/igblast](http://www.ncbi.nlm.nih.gov/projects/igblast)). J~H~, J~D~, and J~k~ gene segment use and somatic mutations therein were determined manually by comparing hybridoma sequences to B6 germline correlates. V~H~ and V~k~ gene designations in [Table I](#tbl1){ref-type="table"} were taken from [@bib27] and from [@bib3], respectively. Heavy and light chain sequences were combined into single files for each member of a clone and then aligned and analyzed with the CustalW analysis function of the program MacVector (v7.2.2) to generate lineage dendrograms.

### Site-directed mutagenesis and expression of antibodies.

The Ig variable genes were amplified from genomic DNA and cloned into the pCR-4-TOPO using sense primers that hybridized upstream of promoter elements identified in [@bib3] and [@bib27] and antisense primers that hybridized to intronic sequences immediately 3′ of expressed J~H~ or J~k~ gene segments ([Table I](#tbl1){ref-type="table"}). Resulting plasmids were used as templates for germline primers (Table S1) in a multiple-site mutagenesis protocol ([@bib52]), modified by increasing the denaturation temperature to 98°C, using Phusion DNA polymerase in PCR and by transforming TOP10 *E. coli* (Invitrogen). The original mutated V~H~-D-J~H~ or revertant V~H~-D-J~H~ genes were excised with EcoR1 and HindIII and ligated into a genomic IgG2b expression vector as previously described ([@bib76]). Light chain fragments were cloned into the EcoRI site of a genomic expression vector containing both the intronic and 3′ kappa enhancer elements. SP2/0/mIL-6 cells were cotransfected with paired heavy and light chain genomic constructs. Mycophenolic acid--resistant transfectomas were screened for the production of IgG antibody. Positive transfectomas were cloned by limiting dilution in 96-well trays. Heavy and light chain pairing was confirmed in a sandwich europium assay, using microtiter trays coated with 1 µg/ml goat anti--mouse kappa and developed with 0.5 µg/ml biotin-labeled goat anti--mouse IgG Ab as described in Antibody binding assays.

### Antibody binding assays.

Antibodies were purified by two rounds of affinity purification and treatments with DNase I and NaCl to remove associated chromatin as previously described ([@bib21]). Antibody purity was assessed by SDS-PAGE. To test for dsDNA binding, 96-well microtiter plates (Microlon high-binding; Greiner Bio-One Inc.) were coated with 0.01% poly-L-lysine (Sigma-Aldrich) followed by 10 µg/ml dsDNA overnight at 4°C. 96-well trays were directly coated (no poly-lysine) with the following: calf thymic chromatin; a mixture of 10 µg/ml of total histones H1, H2A, H2B, H3, and H4 (Roche); and 10 µg/ml ssDNA or cardiolipin in ethanol. Control plates were coated with blocking buffer (PBS with 2 mg/ml BSA, 1 mg/ml gelatin, 0.05% Tween-20, and 0.01% thimerosol) alone. With the exception of the streptavidin-europium binding and release steps, all subsequent steps were performed in blocking buffer with 1 mM EDTA to prevent nonspecific adherence of antibody and detection reagents and degradation of DNA, as previously described ([@bib21]). Experimental mAb at defined concentrations was added to the plates and detected with 0.5 µg/ml biotin-labeled goat anti--mouse IgG followed by 50 ng/ml streptavidin-conjugated Eu^3+^ (PerkinElmer). Eu^3+^ was detected with a time-resolved fluorometer (VICTOR2; PerkinElmer) as previously described ([@bib21]).

### Immunofluorescence assays.

mAbs were tested for autoreactivity against fixed HEp-2 cells (Bio-Rad Laboratories) and against frozen sections of a whole neonatal mouse adhered to ProbeOn Plus microscope slides (Thermo Fisher Scientific). Slides were incubated with mAb for 30 min, washed with PBS for 5 min, and incubated with FITC-labeled sheep anti--mouse IgG antibody (1/200; Sigma-Aldrich) for 30 min. For frozen sections, slides were covered with mounting medium containing DAPI (Vector Laboratories). Pictures were taken with an inverted microscope (Axiovert 200M; Carl Zeiss, Inc.) at 200× (HEp-2) or 100× (frozen sections) magnification. A montage of images taken of frozen sections was assembled using Slidebook 4.1 software (Intelligent Imaging Innovations Inc.).

### Online supplemental material.

Fig. S1 shows an anti-cardiolipin binding assay performed with ANA and engineered revertants. Fig. S2 shows an anti-chromatin binding assay with ANA and engineered revertants. Fig. S3 shows immunofluorescent staining of HEp-2 cells with six ANAs and engineered revertants not represented in [Fig. 5 A](#fig5){ref-type="fig"}. Fig. S4 shows immunofluorescent staining of whole frozen sections of a neonatal mouse with six revertants not analyzed in [Fig. 5 B](#fig5){ref-type="fig"}. Fig. S5 demonstrates that a single kappa Arg mutation is required for high-avidity binding by the J9.11 clone.Table S1 is a composition of all primers used for amplification and cloning throughout the project. Supplemental data shows the sequences of the mutated antibody V regions that were subjected to reversion analysis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20092712/DC1>.
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